ATE484494T1 - Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen - Google Patents

Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen

Info

Publication number
ATE484494T1
ATE484494T1 AT04768065T AT04768065T ATE484494T1 AT E484494 T1 ATE484494 T1 AT E484494T1 AT 04768065 T AT04768065 T AT 04768065T AT 04768065 T AT04768065 T AT 04768065T AT E484494 T1 ATE484494 T1 AT E484494T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical composition
respiratory diseases
indole derivatives
substituted indole
Prior art date
Application number
AT04768065T
Other languages
German (de)
English (en)
Inventor
Roger Bonnert
Anthony Cook
Timothy Luker
Rukhsana Mohammed
Stephen Thom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE484494T1 publication Critical patent/ATE484494T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04768065T 2003-08-18 2004-08-16 Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen ATE484494T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302232A SE0302232D0 (sv) 2003-08-18 2003-08-18 Novel Compounds
PCT/GB2004/003502 WO2005019171A1 (en) 2003-08-18 2004-08-16 Substituted indole derivatives for pharmaceutical composition for treating respiratory diseases

Publications (1)

Publication Number Publication Date
ATE484494T1 true ATE484494T1 (de) 2010-10-15

Family

ID=28450248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04768065T ATE484494T1 (de) 2003-08-18 2004-08-16 Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen

Country Status (18)

Country Link
US (1) US7709521B2 (enExample)
EP (1) EP1656347B1 (enExample)
JP (1) JP4709758B2 (enExample)
AR (1) AR045462A1 (enExample)
AT (1) ATE484494T1 (enExample)
CY (1) CY1110977T1 (enExample)
DE (1) DE602004029580D1 (enExample)
DK (1) DK1656347T3 (enExample)
ES (1) ES2352201T3 (enExample)
MY (1) MY143367A (enExample)
PL (1) PL1656347T3 (enExample)
PT (1) PT1656347E (enExample)
SA (1) SA04250255B1 (enExample)
SE (1) SE0302232D0 (enExample)
SI (1) SI1656347T1 (enExample)
TW (1) TW200510303A (enExample)
UY (1) UY28473A1 (enExample)
WO (1) WO2005019171A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
ES2304010T3 (es) 2004-03-11 2008-09-01 Actelion Pharmaceuticals Ltd. Derivados de tetrahidropiridoindol.
CA2594280C (en) 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
CN102558021A (zh) * 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
WO2013142295A1 (en) 2012-03-21 2013-09-26 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
EP3175856A1 (en) 2006-06-16 2017-06-07 The Trustees of the University of Pennsylvania Methods and compositions for inhibiting or reducing hair loss
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
WO2008012511A1 (en) 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EP2402314B1 (en) 2007-04-11 2013-07-31 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
EP2229358B1 (en) 2007-12-14 2011-03-23 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
CN101932571B (zh) 2008-01-18 2014-04-23 奥克萨根有限公司 具有crth2拮抗活性的化合物
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8461329B2 (en) * 2008-12-25 2013-06-11 Taisho Pharmaceutical Co., Ltd. Isoquinoline derivative
SG10201402346UA (en) * 2009-05-19 2014-10-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2011004182A1 (en) * 2009-07-06 2011-01-13 Astrazeneca Ab Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1h-indole-1-acetic acid
KR20130029368A (ko) * 2010-02-11 2013-03-22 벤더르빌트 유니버시티 Ｍｇｌｕｒ4 알로스테릭 강화제로서 피라졸로피리딘, 피라졸로피라진, 피라졸로피리미딘, 피라졸로티오펜 및 피라졸로티아졸 화합물, 조성물, 및 신경 기능이상을 치료하는 방법
DK2558447T3 (da) 2010-03-22 2014-11-10 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazolderivater og deres anvendelse som prostaglandin d2-receptormodulatorer
KR20130087399A (ko) 2010-06-23 2013-08-06 다이쇼 세이야꾸 가부시끼가이샤 이소퀴놀린 유도체
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
JP6152489B2 (ja) 2014-03-17 2017-06-21 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
EP3256121B1 (en) 2015-02-13 2024-08-07 INSERM - Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
US12201625B2 (en) 2015-07-30 2025-01-21 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human DP-2 gene for detection of susceptibility to hair growth inhibition by PGD2
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
KR102734880B1 (ko) * 2020-10-28 2024-11-27 시오노기 앤드 컴파니, 리미티드 항바이러스 활성을 갖는 아마이드 유도체

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
HUT74614A (en) 1993-02-24 1997-01-28 Merck & Co Inc Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AR017256A1 (es) 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
DK0924209T3 (da) 1997-12-19 2003-08-25 Lilly Co Eli Hypoglykæmiske imidazolinforbindelser
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
EP1990343B1 (en) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindoles
CA2406979A1 (en) * 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US6933316B2 (en) 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
DK1501826T3 (da) 2002-02-01 2007-01-29 Hoffmann La Roche Substituerede indoler som alpha-1-agonister
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097598A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
CN102558021A (zh) 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
CA2654026A1 (en) 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
WO2008000409A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New cxcr2 inhibitors

Also Published As

Publication number Publication date
MY143367A (en) 2011-04-29
JP2007502804A (ja) 2007-02-15
WO2005019171A1 (en) 2005-03-03
CY1110977T1 (el) 2015-06-11
AR045462A1 (es) 2005-10-26
EP1656347B1 (en) 2010-10-13
DK1656347T3 (da) 2011-01-10
PT1656347E (pt) 2010-12-09
JP4709758B2 (ja) 2011-06-22
UY28473A1 (es) 2005-03-31
US7709521B2 (en) 2010-05-04
SE0302232D0 (sv) 2003-08-18
DE602004029580D1 (de) 2010-11-25
ES2352201T3 (es) 2011-02-16
SI1656347T1 (sl) 2011-01-31
PL1656347T3 (pl) 2011-02-28
EP1656347A1 (en) 2006-05-17
US20060264444A1 (en) 2006-11-23
TW200510303A (en) 2005-03-16
SA04250255B1 (ar) 2009-02-25

Similar Documents

Publication Publication Date Title
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE517085T1 (de) Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE517877T1 (de) Neue arzneimittel zur behandlung von atemwegserkrankungen
DE602006005640D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
DE602006002608D1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602004010172D1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1656347

Country of ref document: EP